| Department: |
UAMS Human
Research Advisory Committee |
|
Policy
Number: |
17.1 |
|
Section: |
Special Populations |
|
Effective
Date: |
July 31,
2002 |
|
Revision
Date: |
October 10,
2002 |
SUBJECT:
Children in Research
The
special vulnerability of children makes consideration of involving them as
research subjects particularly important. To safeguard their interests and to
protect them from harm, special ethical and regulatory considerations apply for
reviewing research involving children.
The HRAC may approve research involving children only if special
provisions are met. Children
include all those who have not yet reached their 18th birthday (e.g.,
0 through 17 years old). The HRAC must classify research involving children into
one of four categories and document their discussions of the risks and benefits
of the research study.
Pediatric Risk Category
I: Research Not Involving More Than Minimal
Risk. When the HRAC finds that no
greater than minimal risk to children is present, the HRAC may approve the
proposed research only if the HRAC finds that adequate provisions are made for
soliciting the assent of the children and the permission of their parents or
guardians, as set forth below.
Pediatric Risk Category
II:
Research Involving Greater than Minimal Risk but Presenting the Prospect of
Direct Benefit to the Individual Subjects.
If the HRAC finds that more than minimal risk to children is
present by an intervention or procedure but that the intervention or procedure
holds out the prospect of direct benefit for the individual subject, or by a
monitoring procedure that is likely to contribute to the subject's well‑being,
the HRAC may approve the research only if the HRAC finds that:
1.
The risk is justified by the anticipated benefit to the
subjects
2.
The relation of the anticipated benefit to the risk is at least as
favorable to the subjects as that presented by available alternative
approaches
3.
Adequate provisions are made for soliciting the assent of the children
and permission of their parents or guardians, as set forth below
Pediatric Risk Category
III: Research Involving Greater than Minimal Risk
and No Prospect of Direct Benefit to Individual Subjects, but Likely to Yield
Generalizable Knowledge about the Subject's Disorder or Condition. If the HRAC finds that more than minimal
risk to children is presented by an intervention or procedure that does not hold
out the prospect of direct benefit for the individual subject, or by a
monitoring procedure which is not likely to contribute to the well being of the
subject, the HRAC may approve the research only if the HRAC finds that:
1.
The risk represents a minor increase over minimal risk;
2.
The intervention or procedure presents experiences to subjects that are
reasonably commensurate with those inherent in their actual or expected medical,
dental, psychological, social, or educational situations;
3.
The intervention or procedure is likely to yield generalizable knowledge
about the subjects' disorder or condition which is of vital importance for the
understanding or amelioration of the subjects' disorder or condition; and
4.
Adequate provisions are made for soliciting assent of the children and
permission of their parents or guardians, as set forth below.
Pediatric Risk Category
IV:
Research Not Otherwise Approvable Which Presents an Opportunity to Understand,
Prevent, or Alleviate a Serious Problem Affecting the Health or Welfare of
Children. If the HRAC does not
believe the research proposal meets any of the requirements set forth above, it
may still approve the protocol but only if:
1. The HRAC finds that the research presents
a reasonable opportunity to further the understanding, prevention, or
alleviation of a serious problem affecting the health or welfare of children;
and
2. The Secretary of the Department of Health
and Human Services, after consultation with a panel of experts in pertinent
disciplines (for example: science, medicine, education, ethics, law) and
following opportunity for public review and comment, has determined either that
the research in fact satisfies one of the conditions set forth above, or all of
the following:
a.
The research presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious problem affecting the
health or welfare of children
b.
The research will be conducted in accordance with sound ethical
principles
c.
Adequate provisions are made for soliciting the assent of children and
the permission of their parents or guardians, as set forth below.
Requirements for Permission by
Parents or Guardians and for Assent by Children.
1. Waiver of Parental or Guardian
Permission. If the HRAC determines that a research
protocol is designed for conditions or for a subject population for which
parental or legally authorized representative permission is not a reasonable
requirement to protect the subjects (for example, neglected or abused children),
it may waive the consent requirements described above, provided both (i) an
appropriate mechanism for protecting the children who will participate as
subjects in the research is substituted, and (ii) the waiver is not inconsistent
with Federal, State, or local law. The choice of an appropriate mechanism would
depend upon the nature and purpose of the activities described in the protocol,
the risk and anticipated benefit to the research subjects, and their age,
maturity, status, and condition.
2. Adequate Provisions for Child’s
Assent. The HRAC must find that adequate
provisions are made for soliciting the assent of child subjects when in the
judgment of the HRAC the children are capable of providing assent.
a.
Assent Defined. For purposes of this policy, "Assent"
means a child's affirmative agreement to participate in research. Mere failure to object should not,
absent affirmative agreement, be construed as assent.
b.
In determining whether children
are capable of assenting, the HRAC shall take into account the
ages, maturity, and
psychological state of the children involved.
This judgment may be made for all children to be involved in research under a
particular protocol, or for each child, as the HRAC deems appropriate. The child should be given an explanation
of the proposed research procedures in a language that is appropriate to the
child's age, experience, maturity, and condition.
c.
Waiver of
Assent. If the HRAC determines either of the
following to be true, then the assent of the children
is not a necessary condition for proceeding with the research:
i. The capability of some or all of the
children is so limited that they cannot reasonably be consulted; or
ii. The intervention or procedure
involved in the research holds out a prospect of direct benefit that is
important to the health or well‑being of the children and is available only in
the context of the research.
iii. In circumstances where a child dissents, the child’s parents, at the discretion of the HRAC, may overrule this. When research involves the provision of experimental therapies for life‑threatening diseases such as cancer, however, the HRAC should be sensitive to the fact that parents may wish to try anything, even when the likelihood of success is marginal and the probability of extreme discomfort is high. Should the child not wish to undertake such experimental therapy, difficult decisions may have to be made. In general, if the child is a mature adolescent and death is imminent, the child's wishes should be respected.
iv.
Finally, even where the HRAC determines that the child subjects are
capable of assenting, the HRAC may still waive the assent requirement under
circumstances in which consent may be waived for adults in accordance with
Policy III.D regarding waiver or alteration of informed consent generally.
d. Adequate
Provisions for Parents’ or Guardian’s Permission. The HRAC
must find that adequate provisions are made for soliciting the permission of
each child's parents or legally authorized representative.
i. Research not involving greater than
minimal risk. Where parental
permission is to be obtained, the HRAC may find that the permission of one
parent is sufficient for research not involving greater than minimal risk when
the provisions of section 2 above are met.
ii.
Research involving greater than minimal risk but presenting the prospect of
direct benefit to the individual subjects. Where parental permission is to be
obtained, the HRAC may find that the permission of one parent is sufficient for
research involving greater than minimal risk but presenting the prospect of
direct benefit to the individual subjects when the provisions of section 3 above
are met.
iii.
Research involving greater than minimal risk and no prospect of direct benefit
to individual subjects, but likely to yield generalizable knowledge about the
subject's disorder or condition.
When the research is approved under section 4 above, and permission is to
be obtained from parents, both parents must give their permission unless one
parent is deceased, unknown, incompetent, or not reasonably available, or when
only one parent has legal responsibility for the care and custody of the
child.
iv. Research not otherwise
approvable which presents an opportunity to understand, prevent, or alleviate a
serious problem affecting the health or welfare of children. When the research
is approved under section 6 above and permission is to be obtained from parents,
both parents must give their permission unless one parent is deceased, unknown,
incompetent, or not reasonably available, or when only one parent has legal
responsibility for the care and custody of the child.
Wards of the State or Other
Agency. Children who are wards of the state or
any other agency, institution, or entity can be included in research approved
under Paragraph 4 or Paragraph 5 only if the HRAC finds and documents that such
research is: (1) related to their status as wards; or (2) conducted in schools,
camps, hospitals, institutions, or similar settings in which the majority of
children involved as subjects are not wards.
If
the research is approved, the HRAC must require appointment of an advocate for
each child who is a ward, in addition to any other individual acting on behalf
of the child as guardian. One individual may serve as advocate for more than one
child. The advocate shall be an individual who has the background and experience
to act in, and agrees to act in, the best interests of the child for the
duration of the child's participation in the research and who is not associated
in any way (except in the role as advocate or member of the HRAC) with the
research, the investigator(s), or the guardian organization.